1. United Kingdom Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Futura Medical plc

Futura Medical plc

FUM.L
Futura Medical plcGB flagLondon Stock Exchange
0.49
GBp
-0.06
- -
1.66MMarket Cap
Futura Medical plc
FUM.L
(London Stock Exchange)

Recent

price

0.49

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.01
0.05
0.01
Revenue per Share
-0.02
-0.03
-0.03
-0.03
-0.03
-0.05
-0.04
-0.03
-0.04
-0.04
-0.01
-0.02
-0.02
-0.02
- -
-0.03
Basic EPS, GAAP
-0.02
-0.03
-0.03
-0.03
-0.03
-0.05
-0.03
-0.03
-0.04
-0.03
-0.02
-0.02
-0.02
- -
- -
-0.02
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-0.23
-0.24
-0.26
-0.28
-0.27
-0.3
-0.32
-0.3
-0.32
-0.25
-0.22
-0.21
-0.22
-0.22
-0.21
-0.22
Book Value per Share
0.01
0.04
0.04
0.01
0.11
0.05
0.12
0.08
0.07
- -
- -
0.04
0.02
0.02
0.03
0.01
Tangible Book Value per Share
68
72
75
78
90
100
102
121
132
205
244
271
287
301
302
326
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
3
14
2
Sales/Revenue/Turnover
-1,068.8
-1,327.94
-3,274.57
-682.54
-8,028.47
-20,751.81
-2,673.17
-1,338.73
- -
-35,130.49
- -
- -
- -
-224.57
8.93
-297.99
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
-1
-2
-2
-2
-3
-5
-4
-4
-6
-9
-2
-5
-6
-7
1
-9
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-872.8
-1,148.31
-2,902.2
-595.4
-6,824.38
-17,239.25
-2,170.15
-1,075.27
- -
-28,067.5
- -
- -
- -
-210.03
9.28
-534.62
Profit Margin (%)
1
3
3
1
10
5
13
9
9
- -
1
9
4
3
6
2
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
1
3
3
1
10
5
13
9
9
- -
1
10
5
5
9
3
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
252.29%
199.77%
-68.7%
Free Cash Flow
33.45%
64.73%
320.45%
Net Income, GAAP
-77.85%
-157.24%
-801.52%
Sales/Revenue/Turnover
- -
- -
-87.82%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
3
2024
- -
- -
- -
- -
14
2025
- -
- -
- -
- -
2

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-0.02
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
-0.03

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
Pliant Therapeutics, Inc. (PLRX)
GuiZhou SanLi Pharmaceutical Co.,Ltd (603439.SS)
Sunmax Biotechnology Co., Ltd. (4728.TWO)
XORTX Therapeutics Inc. (XRTX)
TAO Synergies Inc. (TAOX)
Clovis Oncology, Inc. (C6O.DE)
Business
Futura Medical plc develops and commercializes innovative sexual health products focused on topical gel formulations for over-the-counter use. The company offers Eroxon, a clinically proven, fast-acting topical gel for erectile dysfunction that works within 10 minutes and is available without prescription; Eroxon Intense, a stronger-sensation extension in development with home user study results expected in Q1 2026 and potential regulatory approval in H1 2026; and WSD4000, an early-stage topical treatment for impaired sexual response in women with early feasibility study results anticipated in H1 2026. Products target consumers seeking non-prescription alternatives to traditional treatments, with distribution through partners including Haleon in the United States, Cooper Consumer Health in Europe and the United Kingdom, Labatec in the Middle East, and M8 Pharmaceuticals in Mexico; operations span over 15 countries in Europe, the Middle East, North America, and Latin America. Founded in 2001 and headquartered at Surrey Technology Centre in Guildford, United Kingdom, Futura Medical employs a partner-led commercialization strategy to leverage marketing expertise in major markets. In November 2025, the company raises gross proceeds of 2.75 million pounds through a placing and subscription of 275 million new shares at 1 pence each to fund development of Eroxon Intense and WSD4000 amid slower-than-expected Eroxon sales; appoints Alex Duggan as permanent chief executive officer; and pursues US patent milestone payment of US$2.5 million from Haleon in H1 2026 alongside commercial reviews with partners.